FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 195 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR NICE doesn’t recommend olaparib for patients with certain prostate cancers September 13, 2022 The Caregiver Curve March 15, 2021 ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ December 27, 2018 Combination of Azacitidine and Venetoclax in Previously Untreated AML August 18, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence...
